Plus, pipeline setbacks for Sanofi, argenx Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 15 December, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Reserve your spot now.

presented by Strength in rar­i­ty: Why biotech spon­sors are dou­bling down on rare on­col­o­gy con­sor­tia

news In Focus China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in Sanofi’s multiple sclerosis drug flunks Phase 3 trial, faces another PDUFA delay Argenx cans thyroid eye disease trials of Vyvgart Hytrulo Chai Discovery becomes newest AI unicorn, raising $130M Series B at $1.3B valuation Sobi to buy gout biotech Arthrosi for $950M upfront Milestone finally wins FDA approval for arrythmia nasal spray

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

ENDPOINTS PHARMA CHMP calls to reject Anavex's Alzheimer’s pill over impurities, side effects and weak efficacy Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources say 340B sales grew 23% last year, and court battle over pilot program intensifies

in case you missed it 1. GSK spins out corporate VC fund focused on bioelectronic tech 2. Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancers 3. Peer Review Centessa CEO to step down; John Maraganore, Clive Meanwell find CMO for their new cardio bet 4. News Briefing Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor